According to a clinical study, semaglutide shows noticeable weight loss after 4 weeks
For my medullary patients the ones with the FDA warning I'm still saying, until we have better data, I can't recommend it
Given the opposing mechanisms of LPL regulation between adipose tissue and the heart, it is possible that GIP lowers cardiac LPL activity
Fat distribution shifts from hips and thighs (subcutaneous) toward the abdomen (visceral)
Post-marketing surveillance and long-term cardiovascular safety studies reveal no significant safety imbalances ( Concerning SGLT2 inhibitors evaluation, the findings indicate that when compared to a placebo, the use of SGLT2 inhibitors did not demonstrate a significant difference in the risks associated with various adverse events
No, you should never reuse a needle under any circumstances